Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEB071 (Sotrastaurin) in Active, Moderate to Severe Ulcerative Colitis
NCT00572585Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2010
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in ulcerative colitis (UC) comparing AEB071 with Placebo (2 arms). Primary endpoint: Rate of induction of remission at 28 days. Started Apr 2010; status: completed.
02
Drugs
sotrastaurin
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00572585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00572585.